EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sonoma Pharmaceuticals Inc (SNOA) fair value: what the stock is really worth

As of Oct 16, 2026: fair value (intrinsic value) of Sonoma Pharmaceuticals Inc stock $0.22, price $1.12, upside -80.3%, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

SP Sonoma Pharmaceuticals Inc logo Thin data Oct 16, 2026

Sonoma Pharmaceuticals Inc

SNOA · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Quality 42/100
Fair value $0.2210 · Strongly overvalued (−80.3%)
Weak Growth (revenue 5y +0.9 %/yr in USD)
Loss-making · -10.3% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 10/100
Thin data
⚠ Dilution
Watch Sonoma Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$163.00 $1.01 Fair Value $0.2210 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 16, 2026.

How to read this chart

60‑month range $1.01 – $163.00 · fair‑value band $0.1445 – $0.2720 · the $1.12 price screens above the $0.2210 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 16, 2026.

Follow Sonoma Pharmaceuticals in your weekly email

Every Wednesday you see whether Sonoma Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.

Show moreShow less

It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.

The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.

In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution.

The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Stock analysis

Sonoma Pharmaceuticals Inc (SNOA) currently trades at $1.12, while our model-based Fair Value estimate is $0.2210, 80.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.1445 (bear) to $0.2720 (bull), the price of $1.12 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Sonoma Pharmaceuticals Inc reported revenue of $19.5M in FY2026 versus $12.6M in FY2022, a compound +11.5%/yr. Reported net income was −$3.2M in FY2026.

Key figures

Market cap $5.6M · P/S ratio 0.25 · EPS (TTM) $−1.20 · Net margin −16.3% · Return on equity −42.5% · Return on assets (EBIT) −27.2% · Operating margin −0.6% · Revenue (TTM) $21.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −80%, SNOA screens richer than that median.

Fair Value models

Bear $0.1445 Fair Value $0.2210 Bull $0.2720
Price $1.12 · Upside -80.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.1700 $0.2600 $0.3200 55
All 1 models by family
Asset-Based
NCAV (Graham) $0.1700 $0.2600 $0.3200 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 39
How much profit the company makes from its sales and capital
Quality Growth 84
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 19
How calm the share price moves, does not count
Momentum 15
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+36.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Start year 2021 (pandemic). Over 10 years: +7.6% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18.5% (2021) → −12.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

SNOA screens overvalued: fair value 80% below the price. Compare with Merck KGaA →

Compare Sonoma Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 574 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −80.3% · Bottom 25%
Profitability
Return on assets −22.7% · Bottom 25%
Net margin (12 months) −10.3% · Bottom 25%
Operating margin (12 months) −0.6% · Bottom 25%
Growth and dividend
Revenue growth 59.6% · Top 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.79× · Cheaper than median
P/S (12 months) 0.25× · Cheapest 25%
PEG 1.08× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 28
HEALTH (low debt)79 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $75.65 $110.50 +46% vs SNOA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,760 ₹1,936 +10% vs SNOA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.05 ¥50.66 +10% vs SNOA
Haleon plc HLN $9.32 $8.48 −9% vs SNOA
Merck KGaA MRK €143.25 €108.94 −24% vs SNOA
Galderma Group GALD CHF 168.15 CHF 110.94 −34% vs SNOA
Takeda Pharmaceutical Company TAK $18.73 $11.32 −40% vs SNOA
Sandoz Group SDZ CHF 71.02 CHF 40.55 −43% vs SNOA
Teva Pharmaceutical Industries Limited TEVA $39.18 $20.88 −47% vs SNOA
Divi's Laboratories Limited DIVISLAB ₹9,426 ₹1,871 −80% vs SNOA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, survivorship-adjusted Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sonoma Pharmaceuticals Inc · Fair Value
$0.2210 −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sonoma Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/SNOA

Frequently asked questions

Is Sonoma Pharmaceuticals Inc (SNOA) overvalued or undervalued?
As of Oct 16, 2026, our model estimates a fair value of $0.2210 versus a price of $1.12, about −80% upside (overvalued).
What is the fair value of SNOA?
Our model-based fair value for Sonoma Pharmaceuticals Inc is $0.2210 (as of Oct 16, 2026), built from audited fundamentals. The current price: $1.12.
What is the quality score of SNOA?
Sonoma Pharmaceuticals Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sonoma Pharmaceuticals Inc (SNOA)?
Our model-based price target is the fair value of $0.2210 (as of Oct 16, 2026) from 1 valuation models. Cautious scenario $0.1445, optimistic scenario $0.2720. It is a calculation from audited fundamentals, not an analyst target.
What is the Sonoma Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.2210, about −80% upside versus a price of $1.12 (overvalued). Cautious scenario $0.1445, optimistic scenario $0.2720. The calculation is refreshed regularly with new filings.
What is the revenue of Sonoma Pharmaceuticals Inc (SNOA)?
Sonoma Pharmaceuticals Inc reported trailing-twelve-month revenue of about $21.9M (latest available figure, as of Oct 16, 2026).
What is the intrinsic value of Sonoma Pharmaceuticals Inc (SNOA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sonoma Pharmaceuticals Inc it is $0.2210 per share (as of Oct 16, 2026), against a price of $1.12. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sonoma Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Oct 16, 2026, SNOA trades above its calculated fair value: price $1.12, fair value $0.2210, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SNOA?
No. The price is what the market pays today ($1.12); the fair value is what the company's own numbers justify ($0.2210). For Sonoma Pharmaceuticals Inc the two are $0.8990 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sonoma Pharmaceuticals Inc worth?
The market values Sonoma Pharmaceuticals Inc at about $5.6M (market capitalisation, as of Oct 16, 2026). Per share that is $1.12; our models calculate a fair value of $0.2210 per share.
What do the bullish and bearish scenarios say about SNOA?
Our models span a range for Sonoma Pharmaceuticals Inc: cautious scenario $0.1445, base $0.2210, optimistic $0.2720 per share (as of Oct 16, 2026, price $1.12). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of SNOA?
The PEG ratio of Sonoma Pharmaceuticals Inc is 1.08 (P/E divided by earnings growth, as of Oct 16, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sonoma Pharmaceuticals Inc (SNOA)?
Balance-sheet figures for Sonoma Pharmaceuticals Inc (as of Oct 16, 2026): return on equity −42.5%, debt of 0.42 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is SNOA from its 52-week high?
Sonoma Pharmaceuticals Inc trades at $1.12, about 73% below its 52-week high of $4.08 and 11% above the low of $1.01 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2210 is for.
Which stocks are comparable to Sonoma Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sonoma Pharmaceuticals Inc stock attractive at the current price?
The data as of Oct 16, 2026: price $1.12, calculated fair value $0.2210 (−80%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SNOA calculated?
We run Sonoma Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2210, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.4 % above its aggregate fair value. Sonoma Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sonoma Pharmaceuticals Inc (SNOA)?
The closing price on Oct 16, 2026 was $1.12. Our model-based fair value is $0.2210, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sonoma Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.2720). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1445 to $0.2720) leaves room in how you read the outcome.

Key figures of Sonoma Pharmaceuticals Inc

How large is the market capitalisation of Sonoma Pharmaceuticals Inc (SNOA)?
The market capitalisation of Sonoma Pharmaceuticals Inc is $5.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sonoma Pharmaceuticals Inc (SNOA)?
The price-to-sales ratio of Sonoma Pharmaceuticals Inc is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sonoma Pharmaceuticals Inc (SNOA)?
Earnings per share at Sonoma Pharmaceuticals Inc are $−1.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sonoma Pharmaceuticals Inc (SNOA)?
The net margin of Sonoma Pharmaceuticals Inc is −16.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sonoma Pharmaceuticals Inc (SNOA)?
The return on equity (ROE) of Sonoma Pharmaceuticals Inc is −42.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sonoma Pharmaceuticals Inc (SNOA)?
On an EBIT basis the return on assets of Sonoma Pharmaceuticals Inc is −27.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sonoma Pharmaceuticals Inc (SNOA)?
The operating margin of Sonoma Pharmaceuticals Inc is −0.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sonoma Pharmaceuticals Inc (SNOA)?
Revenue at Sonoma Pharmaceuticals Inc is growing +59.6% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sonoma Pharmaceuticals Inc (SNOA) generate?
The free cash flow of Sonoma Pharmaceuticals Inc is −$4.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sonoma Pharmaceuticals Inc (SNOA) hold?
Sonoma Pharmaceuticals Inc holds more cash than debt, $1.6M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sonoma Pharmaceuticals Inc in the live analysis

One click puts Sonoma Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.